Investor Presentaiton

Investor presentation ADA 2019 Slide 9 The FLOW trial is the first dedicated GLP-1 renal outcomes trial to demonstrate that semaglutide delays renal impairment End-stage renal disease (ESRD) often results in chronic dialysis treatment or kidney transplantation¹ C C C C c Healthy kidney ESRD kidney Randomised: >3,000 patients with type 2 diabetes FLOW trial design Semaglutide 1.0 mg Placebo ~20-25 years Event driven • • • 2 in 5 people living with type 2 diabetes will develop chronic kidney disease² Up to 70% of people with type 2 diabetes and chronic kidney disease experience continued deterioration of the kidney function despite the current standard of care3-5 ~10% of the population worldwide is suffering from chronic kidney diseases6 The global dialysis market is currently estimated to be around USD 80 billion? 1 Afkaria et al, Kidney Disease and Increased Mortality Risk in Type 2 Diabetes, J Am Soc Nephrol, 2013; 2 IDF Diabetes Atlas, Eighth edition 2017; 3 Lewis et al. Renoprotective effect of the ARB Irbesartan in patients with T2D and nephropathy (IDNT trial). NEJM 2001; 4 Brenner et al. Renal trial. Effects of losartan on renal and cardiovascular outcomes. NEJM 2001; 5 Lewis et al. The effect of ACE inhibition on diabetic nephropathy. NEJM, 1993; 6 National Kidney Foundation (US), 2015 data; 7 Global Market Insights Inc.; Dialysis Market Global Share Analysis 2024, published November 2018 T2D: type 2 diabetes. Trial objective The FLOW trial is the first dedicated GLP-1 renal outcomes trial and is carried out to demonstrate that semaglutide delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease Inclusion criteria • Patients with type 2 diabetes HbA1c ≤10% Impaired kidney function measured by estimated Glomerular Filtration Rate (eGFR)* Trial initiation: Q3 2019 eGFR ≤75 to ≥50* and UACR >300 to <5,000 mg/g or eGFR <50 to ≥25* and UACR >100 to <5,000 mg/g (20% cap of patients having eGFR ≥60*) novo nordisk

View entire presentation